Last $57.65 USD
Change Today +0.145 / 0.25%
Volume 2.9M
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 12:18 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$57.32
Previous Close
$57.50
Day High
$57.80
Day Low
$56.85
52 Week High
04/22/14 - $58.32
52 Week Low
05/1/13 - $44.60
Market Cap
169.0B
Average Volume 10 Days
11.9M
EPS TTM
$3.48
Shares Outstanding
2.9B
EX-Date
03/13/14
P/E TM
16.6x
Dividend
$1.76
Dividend Yield
3.02%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company’s Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., and Sanofi Pasteur S.A. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

77,300 Employees
Last Reported Date: 02/27/14
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
Executive Vice President and President of Glo...
Total Annual Compensation: $957.3K
Executive Vice President
Total Annual Compensation: $988.9K
Executive Vice President and General Counsel
Total Annual Compensation: $804.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (MRK) Key Developments

FDA Approves Merck's RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U)

Merck announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U). RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in adults 18 through 65 years of age. RAGWITEK is not indicated for the immediate relief of allergic symptoms. The prescribing information for RAGWITEK includes a boxed warning regarding severe allergic reactions. RAGWITEK is contraindicated in patients with severe, unstable or uncontrolled asthma; a history of any severe systemic allergic reaction; a history of any severe local reaction after taking any sublingual allergen immunotherapy; a history of eosinophilic esophagitis; or hypersensitivity to any of the inactive ingredients contained in the product.

Merck & Co. Announces Food and Drug Administration Approves its New Tablet for Grass Allergies, Grastek, for Patients Five to 65 Years Old

Merck & Co. announced the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old. Meant as an alternative to weekly allergy shots, the tablet dissolves under the tongue. Taken daily for a few years, it gradually reduces sensitivity to common grasses, instead of temporarily relieving symptoms including sneezing, runny nose, and itchy, watery eyes. The drug can cause severe allergic reactions and shouldn't be used by patients with severe asthma.

ALK Announces Food and Drug Administration Approval for Merck's Grass Sublingual Allergy Immunotherapy Tablet GRASTEK (GRAZAX)

ALK announced that the US Food and Drug Administration (FDA) has approved the Biologic License Application (BLA) for Merck's grass sublingual allergy immunotherapy (SLIT) tablet GRASTEK(r). GRASTEK(r) is the US trade name of the grass SLIT-tablet which is licensed to Merck (known as MSD outside the USA and Canada) for North America by ALK, and marketed in Europe under the brand name GRAZAX(r). GRASTEK(r) is an allergen extract. In the USA, GRASTEK(r) is indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens. GRASTEK(r) is approved for use in persons 5 through 65 years of age. GRASTEK(r) is not indicated for the immediate relief of allergic symptoms. ALK's partnership with Merck covers the development, registration and commercialization of a portfolio of sublingual allergy immunotherapy tablets in North America. GRASTEK(r) is the first of these products to be approved by the FDA and, following today's approval, Merck is expected to move ahead with its launch plans. The FDA is currently also reviewing Merck's BLA for a SLIT-tablet against ragweed allergy (RAGWITEK(tm)). Following a positive recommendation from the FDA's Advisory Committee in January, a decision by the FDA is expected in second quarter of 2014. The US approval of GRASTEK(r) entitles ALK to a milestone payment from Merck. Consequently, ALK is updating its financial outlook for 2014. The milestone payment will be booked as revenue from SLIT-tablets in North America and ALK now expects operating profit (EBITDA) to be DKK 375-400 million (previously 300-400) before special items, income from product supply, and potential sales royalties in North America. The higher end of this range assumes one additional product development milestone payment from Merck.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $57.62 USD +0.12

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €96.74 EUR -0.25
GlaxoSmithKline PLC 1,651 GBp +8.50
Pfizer Inc $30.69 USD -0.23
Roche Holding AG SFr.255.20 CHF -1.00
Sanofi €76.60 EUR -0.45
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 39.1x
Price/Sales 3.9x
Price/Book 3.4x
Price/Cash Flow 38.4x
TEV/Sales 2.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.